ClinicalTrials.gg
CompletedNCT07690202IMAJEUpdated Nov 19, 2026

Living With Chronic Kidney Disease Without Renal Replacement Therapy: Experience of Women of Childbearing Age

An observational study in Renal Insufficiency, Chronic, sponsored by University Hospital, Caen. Completed at 1 site in France. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-19.

Sponsored by University Hospital, Caen · Observational

How we know

Updated Nov 19, 2026Now CompletedPrimary completion moved+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Other
Time perspective
Cross-sectional
Enrollment
12
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 238 studies in Renal Insufficiency, Chronic with a site in France — 55 open to participants now, 69 under way, 17 of them phase 3. Renal Insufficiency, Chronic · France.

Enrollment
69th of 73
12 · median 165
Started
2026
with 18 others
Observational
73 of 238
20 open now
Registered
231st of 238
by date

Among the 238 studies in Renal Insufficiency, Chronic with a site in France, this one is the 69th largest by enrollment of the 73 observational ones that give a count, is one of 19 that started in 2026, is one of 73 observational ones, and was the 231st registered.

Renal Insufficiency, Chronic

3,098 studies on the registry are indexed under Renal Insufficiency, Chronic; 700 are open to participants now.

Browse Renal Insufficiency, Chronic studies →

Open to participants now

55 of the 238 studies in Renal Insufficiency, Chronic with a site in France are open now. Recruiting first, the newest first:

50 more — sign in →

All 55 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 434 Renal Insufficiency, Chronic studies recruiting now, 245 (56%) set no upper age limit and 110 (25%) stop at 75 or younger; 43 take children under 18; 80 take healthy volunteers.

This study: 18 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 238 studies in Renal Insufficiency, Chronic with a site in France, or all of them as a file.
02

Study summary

Chronic kidney disease (CKD) affects approximately 13% of the global population. This condition is often associated with comorbidities such as diabetes and hypertension. Although its prevalence increases with age, CKD can also affect younger individuals, particularly women of childbearing age. From the early stages, CKD may lead to female-specific clinical manifestations, such as reduced fertility, occurring at a key period of life. These clinical aspects may also be accompanied by concerns about the transmission of hereditary nephropathy and may generate a significant psychological burden. However, current knowledge regarding the lived experience of young women of childbearing age with CKD remains limited, particularly in France.

The main objective of this study is to explore the lived experience of young women with CKD who are not receiving kidney replacement therapy. In this study, lived experience refers to how participants perceive, make sense of, and integrate CKD into their daily lives and future life plans. Twelve participants with CKD, not transplanted and not on dialysis, will be recruited and divided into two groups: six women with genetically determined CKD and six women with non-genetic CKD. This grouping is justified by the fact that the etiology of the disease may profoundly influence lived experience. Genetic CKD is often associated with concerns regarding familial transmission and early medical follow-up, whereas non-genetic CKD may be perceived as an acquired condition occurring later in life. Data will be collected through semi-structured interviews based on a tailored interview guide. Transcripts will be analysed using Interpretative Phenomenological Analysis (IPA), which allows exploration of the meaning that each participant attributes to her experience.

This is an exploratory pilot study aiming to document, for the first time in France, the lived experience of young women with CKD, with a secondary focus on the potential impact of genetic versus non-genetic etiology. Particular attention will be given to themes related to sexual and reproductive health. The findings will contribute to a better understanding of this understudied population and may ultimately improve their clinical care.

Read the detailed description

This study is a qualitative study using Interpretative Phenomenological Analysis (IPA) based on semi-structured interviews. IPA is particularly well suited to exploring the meaning individuals attribute to their lived experiences. The choice of this methodology is justified by the nature of the research question. Exploring the lived experience of patients with a chronic illness requires consideration of a wide range of issues, including identity-related, relational, and emotional dimensions, which go beyond the strictly biomedical aspects usually addressed. Compared with more descriptive qualitative approaches, such as thematic analysis, IPA provides deeper access to the complexity of subjective experience, namely the personal meaning given to illness and the way it is integrated into daily life and future life projects. It is therefore particularly appropriate for highlighting the lived experience of a condition often described as "invisible".

This psychological approach is grounded in a phenomenological perspective, as it explores how participants perceive and experience illness, rather than providing an objective description of symptoms or medical trajectories. It is also based on the principle of double hermeneutics: the researcher seeks to make sense of the participant's account, while the participant seeks to make sense of her own experience. Finally, IPA is idiographic, as it prioritises an in-depth analysis of individual cases before any attempt at generalisation or comparison. The analysis will be conducted on small samples to allow for a detailed and in-depth examination of each case. The sample will therefore consist of 12 participants (two groups of six participants). Participants will be at least 18 years of age and premenopausal.

Data will be collected through semi-structured interviews based on a tailored interview guide. The first part of the interview will be dedicated to a free narrative. The discussion will therefore evolve according to the participant's responses, allowing the researcher to explore the themes that emerge as priorities for the participant. The second part will consist of a more guided exploration, in which topics identified in the literature as relevant will be introduced to allow further discussion. The interview guide will be developed in collaboration with a psychologist. Prior to data collection, it will be tested with an expert patient who is a member of a patient association for individuals with kidney disease, in order to assess the relevance of the questions and adjust them if necessary. This patient will not be included in the study sample. In line with the IPA approach, the interview guide may be modified and refined throughout the study to accommodate emerging themes.

In addition to the interviews, participants will complete the KDQOL-36 questionnaire (Kidney Disease Quality of Life-36). This is a widely used standardized instrument for assessing quality of life in patients with chronic kidney disease. Responses are collected using Likert-type scales, allowing the calculation of domain-specific scores and an overall quality-of-life score. The questionnaire will be administered after the interview in order to avoid influencing participants' narratives and the IPA analysis. The resulting scores will be used for descriptive purposes only and will help situate each participant's overall experience of the disease, thereby enriching the contextual understanding of each interview.

Finally, a comparison between themes emerging from the interviews and the dimensions assessed by the KDQOL-36 will make it possible to identify aspects of lived experience that are potentially not captured or insufficiently addressed by the instrument, but which are nevertheless meaningful for participants.

03

Conditions studied

  • Renal Insufficiency, Chronic

Keywords

  • Chronic kidney disease
  • Women of childbearing age
  • Lived experience
  • Interpretative Phenomenological Analysis (IPA)
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Women of childbearing age with chronic kidney disease (CKD) not receiving renal replacement therapy (i.e., not on dialysis or kidney transplantation), followed at Caen University Hospital (CHU de Caen). Participants will be divided into two groups according to CKD etiology: genetic and non-genetic.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Women aged ≥ 18 years, cisgender, and not menopausal
  • Patients under follow-up at Caen University Hospital for chronic kidney disease
  • Patients not receiving renal replacement therapy (i.e., not on dialysis or kidney transplantation)
  • Patients who have been informed about the study and provided consent to participate

Exclusion criteria

Exclusion Criteria:

  • Patients not covered by a national health insurance system
  • Patients under legal protection (guardianship, curatorship, or legal safeguard)
  • Patients with insufficient proficiency in French (spoken and written) to understand study information, participate in the interview, and complete the quality-of-life questionnaire
  • Patients unable to attend in-person visits at the Centre Universitaire des Maladies Rénales (CUMR)
  • Patients with comorbid conditions other than chronic kidney disease that may interfere with the study objectives (e.g. conditions affecting fertility)
05

Study design

Observational model
Other
Time perspective
Cross-sectional
Enrollment
12 participants (actual)
Patient registry
No

Groups and cohorts

  • Genetic CKD group

    Women of childbearing age diagnosed with chronic kidney disease (CKD) of confirmed or suspected genetic etiology, not receiving renal replacement therapy (i.e., not on dialysis orkidney transplantation).

  • Non-genetic CKD group

    Women of childbearing age diagnosed with chronic kidney disease (CKD) of non-genetic etiology, not receiving renal replacement therapy (i.e., not on dialysis or kidney transplantation).

06

What researchers measure

Primary outcomes

  1. Lived experience of chronic kidney disease in women of childbearing age (without renal replacement therapy)

    Exploration of participants' lived experience of CKD, including perceptions of the disease, impact on daily life, and influence on future life plans, collected through semi-structured interviews and analysed using Interpretative Phenomenological Analysis (IPA).

    Time frame: Baseline (single study visit)

Secondary outcomes

  1. Impact of chronic kidney disease etiology (genetic vs non-genetic) on lived experience

    Exploratory comparison of lived experiences between participants with chronic kidney disease of genetic and non-genetic etiology.

    Time frame: Baseline (single interview)

  2. Emergent themes related to sexual and reproductive health

    Identification of emerging themes related to sexual and reproductive health during semi-structured interviews.

    Time frame: Baseline (single interview)

  3. Health-related quality of life (KDQOL-36)

    Assessment of health-related quality of life using the KDQOL-36 questionnaire, providing domain-specific and overall quality-of-life scores.

    Time frame: Baseline (single interview)

07

Study locations

1 site
  • Centre Universitaire des Maladies Rénales (CUMR), Caen University Hospital
    Caen, 14000, France
08

References and documents

Individual participant data

Plan to share: No — Individual participant data will not be shared due to the sensitive and potentially identifiable nature of qualitative interview data. Participants' confidentiality will be ensured in accordance with ethical and regulatory requirements.

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Ran from Jun 2026 to primary completion in Nov 2026, 4 months.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 19, 2026: primary completion Aug 2027 → Nov 2026 and completion Aug 2027 → Nov 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jul 1, 2026
First posted
Jul 8, 2026
StartActual
Jun 30, 2026
Primary completionActual
Nov 17, 2026was Aug 2027
CompletionActual
Nov 17, 2026was Aug 2027
Last update
Nov 19, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Completed
changed Nov 19, 2026
Primary completion
Aug 2027→Nov 17, 2026 (actual)
Nov 19, 2026
Study completion
Aug 2027→Nov 17, 2026 (actual)
Nov 19, 2026
Show all 1 update
  1. Nov 19, 2026
    Recruiting→Completed
    Primary completion Aug 2027→Nov 17, 2026 (now actual)
    Study completion Aug 2027→Nov 17, 2026 (now actual)
    + 2 other changes: contact details and site details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07690202
Responsible party
Sponsor
First posted
Jul 8, 2026
Start date
Jun 30, 2026
Primary completion
Nov 17, 2026
Completion
Nov 17, 2026
Last update
Nov 19, 2026

Study contacts

Antoine Lanot, MD
principal investigator · University Hospital, Caen

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion